Stockscreener 앱 받기
8.71
9.70%
0.77
전일 마감가:
$7.94
열려 있는:
$8.04
하루 거래량:
66,736
Relative Volume:
1.55
시가총액:
$35.20M
수익:
$147.75M
순이익/손실:
$-284.23M
주가수익비율:
-2.9727
EPS:
-2.93
순현금흐름:
$-317.54M
1주 성능:
+26.42%
1개월 성능:
+54.98%
6개월 성능:
-30.79%
1년 성능:
-20.96%
1일 변동 폭
$7.77
$8.88
1주일 범위
$6.72
$8.88
52주 변동 폭
$4.50
$21.94
Fibrogen Inc Stock (FGEN) Company Profile
명칭
Fibrogen Inc
전화
415-978-1200
주소
350 BAY STREET, SAN FRANCISCO, CA
FGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FGEN
Fibrogen Inc
|
8.71 | 28.72M | 147.75M | -284.23M | -317.54M | -2.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Fibrogen Inc Stock (FGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-06-26 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2023-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-06-26 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-06-02 | 업그레이드 | Stifel | Hold → Buy |
| 2023-01-31 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-01-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-09-22 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-07-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-07-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-04-07 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2021-04-07 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-03-31 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-03-02 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
| 2020-10-26 | 개시 | Raymond James | Underperform |
| 2020-07-10 | 재개 | Stifel | Buy |
| 2020-05-01 | 개시 | Cowen | Market Perform |
| 2020-04-27 | 개시 | BofA/Merrill | Neutral |
| 2019-05-29 | 재개 | Goldman | Neutral |
| 2019-05-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2019-04-12 | 개시 | Piper Jaffray | Neutral |
| 2019-02-11 | 재개 | Stifel | Buy |
| 2018-12-19 | 업그레이드 | Citigroup | Neutral → Buy |
| 2017-08-08 | 재확인 | Leerink Partners | Outperform |
| 2017-08-08 | 재확인 | Stifel | Buy |
| 2017-07-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2017-07-11 | 개시 | Jefferies | Buy |
| 2016-02-11 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
| 2015-12-04 | 개시 | Citigroup | Buy |
| 2015-09-23 | 개시 | Lake Street | Hold |
| 2015-07-29 | 개시 | Citigroup | Buy |
| 2015-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2014-12-09 | 개시 | Stifel | Buy |
모두보기
Fibrogen Inc 주식(FGEN)의 최신 뉴스
Fibrogen FGEN 2025Q2 Earnings Preview Upside Potential on Strong Revenue Growth - AInvest
FibroGen shares surge on FDA support for anemia drug in MDS patients - MSN
FibroGen Inc expected to post a loss of $2.31 a shareEarnings Preview - TradingView
FibroGen shares rise 11.75% intraday after positive FDA meeting for roxadustat Phase 3 trial. - AInvest
Fibrogen: HC Wainwright Raises PT to $43 from $10, Maintains Buy Rating - AInvest
FibroGen stock surges after FDA feedback on roxadustat for MDS anemia - Investing.com India
FibroGen advances roxadustat for anemia in myelodysplastic syndromes By Investing.com - Investing.com Australia
FibroGen advances roxadustat for anemia in myelodysplastic syndromes - Investing.com
FibroGen Announces Positive Type C Meeting with the FDA for - GlobeNewswire
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes - Stock Titan
FibroGen, Inc. (NASDAQ:FGEN) Q4 2024 Earnings Call Transcript - MSN
FibroGen to Report Second Quarter 2025 Financial Results - The Manila Times
FibroGen Q2 2025 Earnings Call: Key Financial Results Coming August 11 After Market Close - Stock Titan
How does FibroGen Inc. compare to its industry peersHigh-yield growth strategies - Jammu Links News
How volatile is FibroGen Inc. stock compared to the marketCapitalize on market trends with confidence - Jammu Links News
What is the dividend policy of FibroGen Inc. stockInvest confidently with professional guidance - Jammu Links News
Is FibroGen Inc. a good long term investmentRapidly growing investment returns - Jammu Links News
How does FibroGen Inc. generate profit in a changing economyGet exclusive access to premium stock research - Jammu Links News
What institutional investors are buying FibroGen Inc. stockCapitalize on momentum-driven stocks - Jammu Links News
What are analysts’ price targets for FibroGen Inc. in the next 12 monthsLightning-fast capital gains - Jammu Links News
Should I hold or sell FibroGen Inc. stock in 2025Get real-time updates on market trends - Jammu Links News
What are the latest earnings results for FibroGen Inc.Consistent triple-digit returns - Jammu Links News
What is the risk reward ratio of investing in FibroGen Inc. stockRealize exceptional returns through smart trading - Jammu Links News
How strong is FibroGen Inc. company’s balance sheetCapitalize on market shifts with expert advice - Jammu Links News
Press Release: FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update - 富途牛牛
Applying big data sentiment scoring on FibroGen Inc.Quick Gain Stock Watch With Indicators Reviewed - metal.it
Short Interest Drops in FibroGen Inc. After RallyMarket Momentum Signal Generator Shows Trends - beatles.ru
FibroGen Inc. Recovery Potential Based on Technical ToolsTechnical Entry Strategy for Beginners Explained - metal.it
Sector Leaders Rotate Capital Into FibroGen Inc.Trade Timing Strategy With Technical Data Explained - metal.it
FibroGen Inc. Hits Oversold Level on RSI IndicatorConsistent Profit Pattern Recognition Tools Shared - metal.it
Published on: 2025-07-29 03:32:03 - metal.it
What are FibroGen Inc. company’s key revenue driversUnprecedented profits - Jammu Links News
Is FibroGen Inc. a growth stock or a value stockUnmatched market performance - jammulinksnews.com
What are the technical indicators suggesting about FibroGen Inc.Consistent wealth multiplication - jammulinksnews.com
Is it the right time to buy FibroGen Inc. stockExplosive returns - jammulinksnews.com
What makes FibroGen Inc. stock price move sharplyCarefully Curated High Return Stocks - metal.it
Why FibroGen Inc. stock attracts strong analyst attentionFree VIP Investment Strategies - metal.it
FibroGen Inc. Stock Analysis and ForecastConsistently superior profits - PrintWeekIndia
Will FibroGen Inc. stock split in the near futureSuperior portfolio returns - jammulinksnews.com
What drives FibroGen Inc. stock priceExplosive returns - PrintWeekIndia
Fibrogen Inc (FGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Fibrogen Inc 주식 (FGEN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO |
Mar 24 '25 |
Buy |
0.35 |
145,000 |
50,663 |
543,329 |
| Schoeneck James A | Director |
Mar 20 '25 |
Buy |
0.35 |
250,000 |
88,000 |
323,722 |
| Schoeneck James A | Director |
Mar 21 '25 |
Buy |
0.34 |
50,000 |
17,040 |
373,722 |
0.24%
3.39%
자본화:
|
볼륨(24시간):